Results 311 to 320 of about 458,490 (361)
Some of the next articles are maybe not open access.
Pharmacologic immunosuppression
Frontiers in Bioscience, 2004Clinical organ transplantation only became a viable treatment option after the advent of effective pharmacologic immunosuppression. Azathioprine and steroids were among the first drugs available for pharmacologic immunosuppression allowed for the first long-term successes in kidney and liver transplantation, though survivors experienced significant ...
Neal R, Barshes +2 more
openaire +2 more sources
Pediatric Transplantation, 2004
Abstract: Advances in maintenance immunosuppression over the past decade has resulted in dramatic improvements in short‐ and long‐term outcomes in organ transplantation as well as a decreased incidence of acute rejection. However, immunosuppressive drugs need to be given long term, lack specificity, and are accompanied by adverse metabolic ...
Nancy R, Krieger, Sukru, Emre
openaire +2 more sources
Abstract: Advances in maintenance immunosuppression over the past decade has resulted in dramatic improvements in short‐ and long‐term outcomes in organ transplantation as well as a decreased incidence of acute rejection. However, immunosuppressive drugs need to be given long term, lack specificity, and are accompanied by adverse metabolic ...
Nancy R, Krieger, Sukru, Emre
openaire +2 more sources
Surgical Clinics of North America, 1994
The present success of organ transplantation is largely due to advances in immunosuppressive therapy. Progress has been made from a cytotoxic strategy associated with a high morbidity rate to a strategy that seeks to alter the activity of cells that regulate the immune response, in order to selectively dampen antidonor responses.
B D, Kahan, R, Ghobrial
openaire +2 more sources
The present success of organ transplantation is largely due to advances in immunosuppressive therapy. Progress has been made from a cytotoxic strategy associated with a high morbidity rate to a strategy that seeks to alter the activity of cells that regulate the immune response, in order to selectively dampen antidonor responses.
B D, Kahan, R, Ghobrial
openaire +2 more sources
Surgical Clinics of North America, 1999
Although several new immunosuppressive medications have been developed in the past decade, many possible avenues are yet to be explored. Although the newer agents have not reflected any clear benefit in patient or graft survival over CsA or tacrolimus, they have been useful in reducing the incidence and severity of rejection, reducing the concomitant ...
A, Jain +4 more
openaire +2 more sources
Although several new immunosuppressive medications have been developed in the past decade, many possible avenues are yet to be explored. Although the newer agents have not reflected any clear benefit in patient or graft survival over CsA or tacrolimus, they have been useful in reducing the incidence and severity of rejection, reducing the concomitant ...
A, Jain +4 more
openaire +2 more sources
Cyclosporine immunosuppression
American Journal of Health-System Pharmacy, 1984The chemistry, pharmacokinetics, mechanism of action, clinical efficacy in organ transplants, adverse effects, and dosage and administration of cyclosporine, a new immunosuppressant, are reviewed. Advice on counseling patients who take the drug is also included. Cyclosporine is a cyclic undecapeptide with a high molecular weight.
D M, Canafax, N L, Ascher
openaire +2 more sources
Transplantation, 2006
Induction immunosuppression is intense, prophylactic therapy used at the time of transplantation based on the empiric observation that more powerful immunosuppression is required to prevent acute rejection early. In the past decade, there has been a growing trend towards the use of specialized agents such as antibody therapies for induction. In general,
openaire +2 more sources
Induction immunosuppression is intense, prophylactic therapy used at the time of transplantation based on the empiric observation that more powerful immunosuppression is required to prevent acute rejection early. In the past decade, there has been a growing trend towards the use of specialized agents such as antibody therapies for induction. In general,
openaire +2 more sources
Trends in Pharmacological Sciences, 1993
Experimental models of autoimmune diseases have demonstrated that such disease can be prevented or treated by selectively interfering with activation of any of these cell types: antigen-presenting cells, autoreactive T cells and regulatory T cells. Luciano Adorini and colleagues discuss these approaches to selective immunosuppression and examine how ...
L, Adorini +3 more
openaire +3 more sources
Experimental models of autoimmune diseases have demonstrated that such disease can be prevented or treated by selectively interfering with activation of any of these cell types: antigen-presenting cells, autoreactive T cells and regulatory T cells. Luciano Adorini and colleagues discuss these approaches to selective immunosuppression and examine how ...
L, Adorini +3 more
openaire +3 more sources
Current Opinion in Immunology, 1992
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion.
openaire +2 more sources
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion.
openaire +2 more sources
Current Opinion in Organ Transplantation, 2012
Elika, Derek, Kiran, Dhanireddy
openaire +2 more sources
Elika, Derek, Kiran, Dhanireddy
openaire +2 more sources